QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsky is investigating potential securities law violations.

NEW YORK, Nov. 9, 2026 /PRNewswire/ — QuidelOrtho Corporation (NASDAQ: QDEL) reported third-quarter 2026 results that included a narrowed full-year revenue outlook and a restructuring program, and QDEL shares fell approximately 14%. If that decline hit your account, you have rights as a shareholder, and the investigation is underway now. QDEL shareholders who suffered losses are encouraged to see whether they can recover their QDEL losses . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com  or by telephone at (212) 363-7500.

QuidelOrtho filed a quarterly report on August 7, 2026. In it, the Company said it anticipated that cash on hand, cash from operations, and amounts available under its Revolving Credit Facility “will be sufficient to fund our near-term capital and operating needs for at least the next 12 months.” That same report showed negative operating cash flow of $143.6 million, with $426.5 million of revolver availability remaining.

Management narrowed its full-year revenue expectations with the third-quarter 2026 results. It also announced a restructuring program, which Company disclosures describe as approximately $100 million and extending through 2027. Levi & Korsinsky’s investigation is focused on QDEL shareholders who lost money in the decline that followed.

If you lost money on QuidelOrtho shares, start your QDEL loss review today  or call (212) 363-7500.

Levi & Korsinsky, LLP  | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com

Frequently Asked Questions About the QDEL Investigation

Q: Which statements are being investigated as potentially misleading?  A: The investigation concerns whether QuidelOrtho made materially false or misleading statements regarding its near-term outlook, including its liquidity and full-year revenue expectations. The Company disclosed narrowed full-year revenue expectations and a restructuring program with its third-quarter 2026 results. The stock price then declined sharply, falling approximately 14%.

Q: When did QuidelOrtho allegedly mislead investors?  A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: Who is eligible to participate in the QDEL investigation?  A: Investors who purchased QDEL stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What do QDEL investors need to do right now?  A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?  A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if my QDEL losses are small — is it still worth contacting a lawyer?  A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate?  A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony?  A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-investigation-notice-levi–korsinsky-notifies-investors-of-pending-investigation-into-quidelortho-qdel-302933780.html

SOURCE Levi & Korsinsky, LLP